Tadenan treatment of prostatic adenoma


如何引用文章

全文:

详细

Tadenan, a drug of plant origin, was given to 27 patients with documented prostatic adenoma for 3-12 months. Home uroflowmonitoring for 1, 3, 6 and 12 months registered positive changes in urinary flow rate and urination volume. Side effects were absent. IPSS and QoL parameters were also assessed.

参考

  1. Kirby R., ed. Textbook of benign prostatic hyperplasia. Oxford; 1996. 331-337.
  2. Breza J., Dzurny O., Borowka A. et al. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr. Med. Res. Opin. 1998; 14 (3): 127-139.
  3. Desgrandchamps F. Clinical relevance of growth factor antagonists in the treatment of benign prostatic hyperplasia. Eur. Urol. 1997; 32 (suppl. 1): 28-31.
  4. Levin R. M., Levin S. S., Zhao Y., Buttyan R. Cellular and molecular aspects of bladder hypertrophy. Eur. Urol. 1997; 32 (suppl. 1): 15-21.
  5. Levin R. M., Das A. K. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol. Res. 2000; 28 (3): 201-209.
  6. Вишневский Е. Л. и др. Урофлоуметрия. М.: Печатный город; 2004.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2009
##common.cookie##